MicroRNA-mediated regulation of KRAS in cancer

Journal of Hematology & Oncology

Frank J Slack¹  Minlee Kim¹ 

[1] Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston 02215, MA, USA

关键词: rs712;    rs61764370;    KRAS-variant;    Single nucleotide polymorphism (SNP);    Sequence variant;    Cancer;    KRAS;    microRNA (miRNA);   

Others  :  1144167
DOI  :  10.1186/s13045-014-0084-2

 received in 2014-09-26, accepted in 2014-11-06,  发布年份 2014

【 摘 要 】

While microRNAs (miRNAs) and the KRAS oncogene are known to be dysregulated in various cancers, little is known about the role of miRNAs in the regulation of KRAS in cancer. Here we review a selection of studies published in 2014 that have contributed to our understanding of the molecular mechanisms of KRAS regulation by miRNAs and the clinical relevance of sequence variants that may interfere with functional miRNA-mediated KRAS regulation.

【 授权许可】

   
2014 Kim and Slack; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kim M, Kasinski AL, Slack FJ: MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011, 12:319-321.
• [2]Kasinski AL, Slack FJ: Epigenetics and genetics: microRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Publishing Group 2011, 11:849-864.
• [3]Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531.
• [4]Johnson SM, Großhans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
• [5]Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010, 70:6015-6025.
• [6]Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B: Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 2012, 7:e38847.
• [7]Shin K-H, Bae SD, Hong HS, Kim RH, Kang MK, Park N-H: miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011, 404:896-902.
• [8]Gastaldi C, Bertero T, Xu N, Bourget-Ponzio I, Lebrigand K, Fourre S, Popa A, Cardot-Leccia N, Meneguzzi G, Sonkoly E, Pivarcsi A, Mari B, Barbry P, Ponzio G, Rezzonico R: miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. Carcinogenesis 2014, 35:1110-1120.
• [9]Liao W-T, Ye Y-P, Zhang N-J, Li T-T, Wang S-Y, Cui Y-M, Qi L, Wu P, Jiao H-L, Xie Y-J, Zhang C, Wang J-X, Ding Y-Q: MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol 2014, 232:415-427.
• [10]Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene 2014, 33:2454-2463.
• [11]Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee D-H, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ 2014, 21:720-734.
• [12]Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller R-U, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB: A SNP in a let-7 microRNA complementary site in the KRAS 3’ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008, 68:8535-8540.
• [13]Cerne J-Z, Stegel V, Gersak K, Novakovic S: KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 2012, 12:105. BioMed Central Full Text
• [14]Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J: A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011, 12:377-386.
• [15]Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB: A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010, 70:6509-6515.
• [16]Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller R-U, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB: A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 30:1542-1550.
• [17]Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS: A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med 2012, 4:206-217.
• [18]Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, LaBonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ: A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011, 22:104-109.
• [19]Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M: The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 2013, 23:142-147.
• [20]Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT: KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 2010, 69:51-53.
• [21]Pharoah PDP, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, et al.: The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011, 17:3742-3750.
• [22]Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH: Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer 2012, 12:534. BioMed Central Full Text
• [23]Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB: Association study of the let-7 miRNA-complementary site variant in the 3′ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 2014, 20:3319-3327.
• [24]Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J: The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLoS One 2014, 9:e94167.
• [25]Wang W-Y, Chien Y-C, Wong Y-K, Lin Y-L, Lin J-C: Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck 2012, 34:663-666.
• [26]Li Z-H, Pan X-M, Han B-W, Guo X-M, Zhang Z, Jia J, Gao L-B: A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol 2013, 34:3159-3163.
• [27]Pan X-M, Sun R-F, Li Z-H, Guo X-M, Zhang Z, Qin H-J, Xu G-H, Gao L-B: A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol 2014, 35:831-835.
• [28]Jin H, Liang Y, Wang X, Zhu J, Sun R, Chen P, Nie X, Gao L, Zhang L: Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol 2014, 31:221.
• [29]Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ: Extensive sequence variation in the 3′ untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle 2014, 13:1030-1040.
• [30]Sabarinathan R, Wenzel A, Novotny P, Tang X, Kalari KR, Gorodkin J: Transcriptome-wide analysis of UTRs in non-small cell lung cancer reveals cancer-related genes with SNV-induced changes on RNA secondary structure and miRNA target sites. PLoS One 2014, 9:e82699.